Literature DB >> 12819642

Antiplatelet therapy in peripheral arterial disease. Consensus statement.

.   

Abstract

OBJECTIVES: Antiplatelet agents are commonly prescribed to reduce the risk of myocardial infarction, stroke and graft occlusion in patients with peripheral arterial disease (PAD). The objective was to summarise current evidence and provide recommendations on the use of antiplatelet agents in PAD.
METHODS: A consensus group was assembled including 20 specialists from a variety of fields involved in the management of patients with PAD. Data was circulated in a systematic manner prior to a main consensus meeting held in November 2001. The document subsequently produced was circulated within the group to ensure agreement in the interpretation and presentation of its findings.
RESULTS: Consensus recommendations are provided in 7 common or contentious scenarios in PAD. The recommendations are graded to reflect the evidence available and interpretations of the group. Although the document provides recommendations, it is stressed that they must be interpreted in the light of individual patient circumstances.
CONCLUSION: Antiplatelet agents have an important role in the management of patient with PAD. Although this document provides consensus recommendations, the optimum treatment in many scenarios remains unclear due to a lack of focussed clinical trials in PAD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819642     DOI: 10.1053/ejvs.2002.1927

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

Review 2.  Cilostazol for intermittent claudication.

Authors:  Rachel Bedenis; Marlene Stewart; Marcus Cleanthis; Peter Robless; Dimitri P Mikhailidis; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2014-10-31

3.  Cilostazol for intermittent claudication.

Authors:  Tamara Brown; Rachel B Forster; Marcus Cleanthis; Dimitri P Mikhailidis; Gerard Stansby; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2021-06-30

4.  Effect of ramipril on renal function in patients with intermittent claudication.

Authors:  Simon D Hobbs; Martin W Claridge; Antonius B M Wilmink; Donald J Adam; Mark E Thomas; Andrew W Bradbury
Journal:  Vasc Health Risk Manag       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.